3 / 7
Page 53
Notes:
allied
academies
J Med Oncl Ther 2017 Volume 2 | Issue 3
International Conference on
Oncology and Cancer Therapeutics
October 30- November 01, 2017 | Chicago, USA
Clinicopathological features and prediction values of HDAC1, 2, 3 and 11 in classical Hodgkin lymphoma
Xiaojian Liu
1
, Renhong Huang
1
, Xiaowei Zhang
1
, Zhijun Min
1
, Shune Yang
2
and
Xiyan Wang
2
1
Fudan University Pudong Medical Center, China
2
Xinjiang Medical College, China
H
istone deacetylase (HDAC) is involved in multiple
physical and pathological processes in lymphoma.
The aims of this study were to investigate the expression
of HDAC1, 2, 3 and 11, and to evaluate the correlation of
HDAC1, 2, 3, 11 expressions with survival in cHL patients.
Within the 28 cHL cases investigated, HDAC1, 3 and 11 were
more highly expressed in Hodgkin Reed-Sternberg (HRS)
cells, while HDAC2 showed less expression. Expression of
HDAC2 was correlated with pathological type (P=0.012).
Other clinicopathological parameters showed no significant
correlation with expression of HDAC2, 3 or 11 in survival
(P>0.05). The 10-year total survival rate showed that bulky
disease was a significant prognostic factor (P=0.028).
Higher expression of HDAC1 predicted shorter progression-
free survival (PFS) and overall survival (OS) in cHL patients
(P<0.05), and higher expression of HDAC11 is potentially
correlated with lower OS (P=0.05). These results encourage
further investigation on the role of HDACs in cHL.
Speaker Biography
Xiaojian Liu did his Bachelor’s degree in XuzhouMedical University, China. He worked as
an Oncologist at Jiangsu Cancer Hospital, Nanjin, China and did his Master’s degree at
Suzhou Medical College, Suzhou, China. Again, he worked as an Oncologist at Shanghai
Dongfang Hospital, Shanghai, China. He did his Doctoral degree at Shanghai Cancer
Center, Fudan University, Shanghai, China. Now, he is working in the Department of
Medical Oncology, Shanghai Cancer Center- Fudan University, Shanghai, China.
e:
lxj068@hotmail.com